Invited Speaker



Update time:2024-03-14 22:28

Male,1975-03-25,M.D,Ph.D. Associate professor in the School of Clinical Medicine of Tsinghua University, Executive Deputy Director of the Digital Health Innovation Center at the School of Clinical Medicine of Tsinghua University, Vice Director of the Hepato-Pancreato-Biliary Surgery Department at Beijing Tsinghua Changgung Hospital.

Dr. Feng has expertise and over 27 years of experience in the areas of Hepatobiliary surgery, from surgical procedures to clinical studies. He has studied in Third Military Medical University, Tokyo University, and Tsinghua University,specializing in the diagnosis and treatment of hepatocellular carcinoma. Much efforts have been made in epidemiology, pathophysiology, diagnosis and surgical treatment of hepatobiliary diseases in China. He has a surgical qualification of radiofrequency ablation and other minimally invasive techniques, as well as all kinds of hepatectomy, radical resection of hilar cholangiocarcinoma, other complex surgical operations and perioperative management. In 2021, under the leadership of Academician Dong Jiahong, leading a team to implement the first case of Y90-SIRT in China Mainland in Hainan.

 Recently,he devoted in medical engineering cross work. construction of the National Healthcare &Medical Big-Data Innovation Application Platform. Hosted the research and development of a Remote Digital Clinical Research Platform, which won the Gold Award at the 75th Nuremberg International Invention Exhibition in Germany, Published over 40 papers and a new type of textbook titled "Innovative Application of Health and Medical Big Data".

Topic title: Starting from the treatment of liver cancer with yttrium 90 SIRT to the interdisciplinary project of medical science and engineering.


Hepatocellular carcinoma is a major disease that threatens the health of people in China. Due to its insidious onset, most patients are already in the middle or late stage at the time of initial diagnosis, losing the chance of surgical resection. Yttrium 90 selective internal radiotherapy is the preferred local treatment option for these patients, with the advantages of powerful tumor shrinkage, enlarging the remaining liver, and high efficiency and minimally invasiveness. Based on the largest Yttrium 90 intervention center, the author reported the current status of 90Y-SIRT in China and the most recent preliminary result. Finally give some perspective in the medical-engineering cross field study.

Congress has ended
Important Dates
Conference Dates
March 29-31, 2024
Deadline for Submission of Abstract

December 31, 2023

Still open for submission

Notification of Abstract Acceptance

January 15, 2024

January 25, 2024